Brief: G1 Therapeutics Says Initial Results From Phase 2 Mechanism Of Action Trial In Breast Cancer Show That Single Dose Of Trilaciclib Favorably Alters The Tumor Microenvironment
07/12/2022 23:11
Dec 7 (Reuters) - G1 Therapeutics Inc GTHX.O :
* INITIAL RESULTS FROM PHASE 2 MECHANISM OF ACTION TRIAL IN
EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER SHOW THAT A SINGLE
DOSE OF TRILACICLIB FAVORABLY ALTERS THE TUMOR MICROENVIRONMENT
Source text for Eikon: ID:nGNX8XnyvQ
Further company coverage: GTHX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on G1 Therapeutics
See all newsG1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Ralph Lauren, Illumina, Disney
U.S. STOCKS ON THE MOVE-Walt Disney, SpringWorks, Shopify